Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was retrospectively evaluated to assess efficacy and impact of clinical characteristics on outcome.
| P A TI E NT S A ND M E TH ODS
Charts of adult pITP patients followed at 17 Centers, representative of the Italian territory, on TPO-RA treatment and who underwent TPO-RA switch between December 2009 and December 2015 were retrospectively reviewed to collect demographic and clinical data. Primary ITP and response to therapy were defined according to the International Working Party guidelines. 14 To be included in the analysis, the minimum required follow-up after switch was 1 month for non responders and 2 months for responders. Analysis of associations between clinical parameters and outcome was performed at 3 months from switch. For analysis, patients were grouped into 5 categories according to the clinical setting which had led to TPO-RA switching: (a) 1 st TPO-RA failure-i.e., no response to either one TPO-RA administered before switch; (b) loss of response-i.e., desired platelet count achieved but not sustained over TPO-RA sequence; adverse events; outcome and follow-up after switching were recorded by the participating Centers in a dedicated case report form for each patient enrolled.
Adverse events were graded according to Common Terminology
Criteria for Adverse Events (CTCAE, also called "common toxicity criteria"). Toxicity was graded as mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), with specific parameters according to the organ system involved or death (Grade 5). 16 This observational retrospective collaborative study was approved by the Hospital Review Board of all the participating Centers. 
| Statistical Analysis

| Platelet count fluctuation subgroup
Compared to the rest of the study group, switching because of platelet count fluctuation was associated with previous splenectomy (P 5 .001),
but not with lines of therapy; no association was also found with age or ITP duration. Maximum product dose had been administered to 45.5% of these patients prior to switch.
| Patient's preference subgroup
All patients who underwent switching for personal preference switched from romiplostim to eltrombopag. First TPO-RA maximum product dose had been administered to 62.5% of these patients prior to switch.
| Adverse events subgroup
Sixteen patients reported symptoms or developed laboratory or clinical signs which led to 1 st TPO-RA discontinuation and the majority of of these patients prior to switch. Compared to the rest of the study group, these patients were older (P 5 .021) and each additional year increase in patient's age determined a 5% increase in the odds of developing adverse events.
Except for the ocular cataract and the two thrombotic complications observed in the eltrombopag group (Supporting Information Table   S1 ), all adverse events were mild (grade 1 or 2; only one grade 3 hepatotoxicity on eltrombopag was recorded), resolved upon drug discontinuation, are listed in the manufacturer's brochure and are largely overlapping between the two molecules.
3.2 | Outcome after switching: Short-term results Table 2 and Figure 1 summarizes outcome according to the clinical setting which had led to TPO-RA switching.
The association between clinical parameters and outcome after switch is shown in Table 3 .
Overall, 69/106 patients (65%) achieved, regained or maintained a response upon switching. Either one TPO-RA switch sequence was equally effective in yielding a response and the outcome was not associated with gender or age at 1 st TPO-RA.
On the contrary, disease duration at 1 st TPO-RA was associated with a trend toward lower probability to respond to switch (P 5 .066). Moreover, lines of previous therapy were associated with lower response rates (P 5 .020): each additional line of therapy was associated with a 30% increase in the odds of being a non responder to switch. However, splenectomy status had no impact on response. A trend toward lower probability of response to switch with increasing number of lines of previous therapy was observed, however this association did not reach statistical significance (P 5 .073).
| Efficacy issues subgroups
Response rates significantly differed according to reason for switching ( In one patient response loss was secondary to development of neutralizing antibodies to romiplostim; platelet response was regained upon switching to eltrombopag.
| Nonefficacy issues subgroups
Of the 35 patients who underwent switch for issues other than efficacy, 28 (80%) maintained a response on the 2 nd TPO-RA and this response rate was significantly higher compared with the group of patients who were switched for efficacy issues (P 5 .030).
Response rates were slightly different in the 3 subgroups of patients, as shown in Table 2 . Platelet count fluctuations resolved in 4 (44.4%) of the 9 patients who maintained a response after switching.
Four patients (1 platelet count fluctuations, 3 patient's preference) underwent "double switch" (i.e., romiplostim ! eltrombopag ! romiplostim): re-exposure to romiplostim was not associated with response loss.
| Outcome after switching: Long-term results
Data on long-term outcome was available for 53/69 patients (76.8%).
One patient (patient's preference subgroup) was lost to follow-up after 
| D ISC USSION
Use of TPO-RA enables a high fraction of ITP patients failing immunosuppressive treatments or splenectomy to achieve safe platelets counts 9,10 and our data confirms the efficacy and safety profile of these agents. Among the 546 patients on either romiplostim or eltrombopag, only 71 (13%) switched due to nonefficacy issues, while adverse events accounted for an expected 3% of cases. 17, 18 Conversely, TPO-RA switching in every day clinical practice does not seem to be an uncommon event since it was considered a therapeutic option in almost 20%
of the patients in our cohort. However this figure may be underesti- Overall, 65% of patients achieved, regained or maintaineddepending upon reason for switching-a platelet response after switch.
However, short-term response rates differed markedly between patients who did not respond to the 1 st TPO-RA compared to all other subgroups analyzed and no differences in terms of gender, ITP duration at 1 st TPO-RA, lines of previous therapy or splenectomy status could explain this difference in response rates. Although no study directly comparing efficacy of eltrombopag vs. romiplostim has ever been conducted, the lowest efficacy results in our patients who switched for failure to respond to the 1 st TPO-RA suggests that a fraction of ITP patients might indeed be "primary refractory" to treatment with the two TPO-RA currently available for yet unknown reasons. These patients tended to be younger than those losing response while on 1 st TPO-RA. However, our results are not sufficient to support a role of older age in determining response to TPO-RAs. We have no data supporting defective platelet production (e.g., decreased bone marrow cellularity or absence of megakaryocyte hyperplasia; platelet turnover studies) with advancing age. Moreover, no statistically significant association between age or splenectomy status and response rates was found in all groups analyzed.
Previous studies on a smaller cohort of patients, 12 suggested that romiplostim might be more effective compared to eltrombopag in rescuing patients. This was not confirmed by our data and no significant difference in outcome was observed with the two available TPO-RA agents: both were equally effective in achieving, regaining or maintaining a platelet response upon switching. Only number of lines of previous therapy was associated with lower response rates and, although not statistically significant, disease duration at 1 st TPOadministration also seemed to have an impact on the probability to respond to switch.
Contrary to the results reported by Gonz ales-Porras et al., 13 we
were not able to find an association between not having received the maximum product dose of the 1 st TPO-RA and a higher response rate after switching.
As already reported, 12 However, this specific question was not directly addressed in the present study.
Re-exposure to romiplostim in the 4 patients who underwent "double switch" was not associated with response loss, confirming absence of tachyphylaxis with this TPO-RA. In one patient loss of response was associated with development of neutralizing antibodies to romiplostim, a rare adverse event listed by the manufacturer which has also been described outside controlled trials. 19 Long-term follow-up data, although limited to only a fraction of patients, shows that response to switch tends to be maintained over time and may herald sustained responses leading to treatment discontinuation in some patients. However, although responding to TPO-RA, a fraction of patients undergo splenectomy. Quality of life issues (e.g., frequent hospital visits, alimentary restrictions, route of administration of the agent), therapy and laboratory monitoring costs probably favor the surgical approach in a minority of cases.
The main limitation of our study is its retrospective nature.
However, our results in a large cohort of adult pITP patients are in line with those reported by Khellaf 12 and Gonzales-Porras 13 and confirm that TPO-RA switch can be a safe and appealing treatment option for ITP patients who experience suboptimal results with either agent.
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